BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Pulmonx (LUNG)PulmonxEarnings

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Related news

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

PULMPulmatrix2026-08-13 12:15 EST

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

XAIRBeyond Air2026-08-13 11:00 EST

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

STIMNeuronetics2026-08-11 11:50 EST

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

INSMInsmed2026-08-06 11:00 EST

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Stock data

Close
1.91 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States